Gritstone bio (GRTS)
(Delayed Data from NSDQ)
$0.66 USD
+0.01 (1.44%)
Updated Jul 25, 2024 04:00 PM ET
3-Hold of 5 3
F Value F Growth B Momentum F VGM
Price, Consensus and EPS Surprise
GRTS 0.66 +0.01(1.44%)
Will GRTS be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for GRTS based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for GRTS
Y-mAbs Therapeutics, Inc. (YMAB) Reports Q1 Loss, Misses Revenue Estimates
Xoma (XOMA) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
GRTS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Here's How Cresco Labs (CRLBF) is Placed Before Q1 Earnings
Should SNDL (SNDL) be in Your Portfolio Ahead of Q1 Earnings?
Should You Buy Hims & Hers Health (HIMS) Ahead of Q1 Earnings?
Other News for GRTS
Gritstone to host KOL event to discuss GRANITE cancer vaccine program
Gritstone bio to Host Virtual KOL Event to Discuss Unmet Need and Potential Role of Its Personalized Cancer Vaccine, GRANITE, in Metastatic Microsatellite Stable Colorectal Cancer (MSS-CRC)
Gritstone bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Analysts Offer Insights on Healthcare Companies: Gritstone Oncology (GRTS) and Clene (CLNN)
Forecasting The Future: 4 Analyst Projections For Gritstone Bio